BET bromodomain inhibitor (b)
CAS No. 1380087-89-7
BET bromodomain inhibitor (b)( CPI0610 | CPI 0610 | CPI-0610 )
Catalog No. M11568 CAS No. 1380087-89-7
CPI-0610 is a potent, selective, and cell-active BET bromodomain inhibitor CPI-0610 inhibits BRD4-BD1 with IC50 of 39 nM in time-resolved fluorescence energy transfer (TR-FRET ) binding assay.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 104 | In Stock |
|
| 5MG | 187 | In Stock |
|
| 10MG | 279 | In Stock |
|
| 25MG | 556 | In Stock |
|
| 50MG | 842 | In Stock |
|
| 100MG | 1260 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBET bromodomain inhibitor (b)
-
NoteResearch use only, not for human use.
-
Brief DescriptionCPI-0610 is a potent, selective, and cell-active BET bromodomain inhibitor CPI-0610 inhibits BRD4-BD1 with IC50 of 39 nM in time-resolved fluorescence energy transfer (TR-FRET ) binding assay.
-
DescriptionCPI-0610 is a potent, selective, and cell-active BET bromodomain inhibitor CPI-0610 inhibits BRD4-BD1 with IC50 of 39 nM in time-resolved fluorescence energy transfer (TR-FRET ) binding assay.
-
In VitroPelabresib (0-1500 nM; 72 hours; Multiple myeloma cell lines and primary MM cells) treatment reduces the viability of MM cells in a dose-dependent manner.Pelabresib (800 nM; 72 hours; INA6 and MM.1S cells) treatment leads to G1 cell cycle arrest.Pelabresib (800 nM; 72 hours; INA6 and MM.1S cells) treatment significantly increases apoptosis in MM cells after 72 hours. Cell Viability Assay Cell Line:Multiple myeloma (MM) cell lines and primary MM cells Concentration:0 nM, 200 nM, 400 nM, 600 nM , 800 nM, 1000 nM, 1200 nM, or 1500 nM Incubation Time:72 huors Result:Decreased viability of MM cells in a dose-dependent manner. Cell Cycle Analysis Cell Line:INA6 and MM.1S cells Concentration:800 nM Incubation Time:72 hours Result:Indeced G1 cell cycle arrest.Apoptosis AnalysisCell Line:INA6 and MM.1S cells Concentration:800 nM Incubation Time:72 hours Result:MM cells apoptosis was increased after 72 hours.
-
In VivoPelabresib (30-60 mg/kg; oral administration; for 28 days; MV-4-11 mouse xenograft model) treatment results in substantial suppression of tumor growth over the time period examined (41%, 80%, and 74% tumor growth inhibition, respectively), without any significant body weight loss in the animals. Animal Model:MV-4-11 mouse xenograft modelDosage:30 mg/kg once daily, 30 mg/kg twice daily, or 60 mg/kg once daily Administration:Oral administration; for 28 days Result:Suppressed of tumor growth, without any significant body weight loss in the animals.
-
SynonymsCPI0610 | CPI 0610 | CPI-0610
-
PathwayCell Cycle/DNA Damage
-
Targetc-Myc
-
RecptorMYC| BRD4-BD1
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1380087-89-7
-
Formula Weight365.81
-
Molecular FormulaC20H16ClN3O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: 10 mM
-
SMILESO=C(N)C[C@@H]1N=C(C2=CC=C(Cl)C=C2)C3=CC=CC=C3C4=C1ON=C4C
-
Chemical Name(S)-2-(6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Xiao Y, et al. Rheumatology (Oxford). 2015 Aug 3
molnova catalog
related products
-
MYCi975
MYCi975 is an orally active inhibitor of MYC.MYCi975 inhibits P493-6, MV411,SK-N-B2 cells viability in an MYC-dependent manner(IC50s of 3.7, 3.9, 6.4 μM, respectively).The initial lead, MYC inhibitor 361 (MYCi361), suppressed in vivo tumor growth in mice, increased tumor immune cell infiltration, upregulated PD-L1 on tumors, and sensitized tumors to anti-PD1 immunotherapy. However, 361 demonstrated a narrow therapeutic index.
-
EN4 MYC inhibitor
EN4 MYC inhibitor is a covalent ligand that targets cysteine 171 (C171) of MYC.
-
10058-F4
10058-F4 is a specific c-Myc inhibitor that disrupts the association between the c-Myc and Max.
Cart
sales@molnova.com